Drugs / Evening Primrose Oil

Trials 4 · a red edge is where a trial was stopped

20082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06539975 Dec 2024 → Sep 2025 overdue Assiut University Not yet recruiting No outcome recorded
Phase 43 trials
Phase 4 NCT03584698 Sep 2019 → Jan 2021 pregnancy disorder with abortive outcome Assiut University Completed No outcome recorded
Phase 4 NCT00878670 Mar 2009 → Oct 2010 atopic eczema, neurodermatitis Max Zeller Soehne AG Completed No outcome recorded
Phase 4 NCT00999921 Jan 2008 → Aug 2014 benign mammary dysplasia, breast fibroadenoma, breast fibrocystic disease Medical College and Hospital Kolkata Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT03698734 Comparator Nov 2018 → Nov 2019 pregnancy disorder with abortive outcome Ain Shams University Unknown No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Evening Primrose Oil ClinicalTrials.gov intervention name — accepted as the source's own label NCT03584698
3

NCT03698734

NCT06539975

NCT00999921

Known as EPO “Evening primrose oil (EPO) contains high amounts of GLA.” PMID 24435467 Jan 2014
1

“Evening primrose oil(EPO)” NCT03698734

Known as Oenothera seminis oleum “One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid.” NCT00878670
Known as Primrose plus “women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.” NCT03584698
Route Oral “Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening.” NCT00878670